This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Pharma Stock Roundup: NVS, RHHBY Earnings, AZN, PFE Coronavirus Vaccine Early Data
by Kinjel Shah
Pfizer (PFE) and AstraZeneca (AZN) announce early data on their coronavirus vaccine candidates. Novartis (NVS) and Roche (RHHBY) announce second-quarter results.
Roche's (RHHBY) 1H20 Sales Hit by the Coronavirus Pandemic
by Zacks Equity Research
Roche's (RHHBY) performance in first-half 2020 was unimpressive as it bears the brunt of the COVID-19 outbreak.
Biogen to Pit Spinraza Against Novartis' Zolgensma in Phase IV
by Zacks Equity Research
Biogen (BIIB) intends to start a phase IV study for the assessment of Spinraza's safety in infants and children with SMA who showed a suboptimal clinical response to Novartis' Zolgensma.
AbbVie's Rinvoq Meets Late-Stage Eczema Study Endpoints
by Zacks Equity Research
AbbVie's (ABBV) JAK inhibitor, Rinvoq monotherapy achieves improvement in skin clearance and reduction in itch in significantly higher proportion of atopic dermatitis patients in a phase III study.
Company News for Jul 22, 2020
by Zacks Equity Research
Companies In The News Are: PM, SYF, NVS, PACR.
Novartis' (NVS) Q2 Earnings Surpass Estimates, Sales Miss
by Zacks Equity Research
Novartis' (NVS) second-quarter 2020 sales take a hit due to the coronavirus pandemic.
Lilly's Plaque Psoriasis Candidate Meets Phase III Study Goals
by Zacks Equity Research
Lilly's (LLY) autoimmune disorder candidate, mirikizumab, superior to Cosentyx in a phase III study for patients with moderate-to-severe plaque psoriasis.
Bristol-Myers' (BMY) CAR T Cell Therapy Gets EMA Validation
by Zacks Equity Research
Bristol-Myers' (BMY) MAA for its experimental candidate, liso-cel, gets validated by EMA.
Merck's NDA for Heart Failure Candidate Gets Priority Review
by Zacks Equity Research
FDA decision on Merck (MRK) and its Germany-based partner Bayer's vericiguat as a treatment to reduce heart failure is expected in January 2021.
What To Expect From The Crazy Earnings Season Ahead
by Daniel Laboe
Are Netflix's disappointing results a foreshadowing of what is to come from the most parabolic tech stocks this earnings season?
Ceylad Gets FDA Nod to Begin Phase I Study on CAR T Candidate
by Zacks Equity Research
Celyad (CYAD) gets the FDA's permission to begin a phase I study on its lead CAR T candidate, CYAD-211, for the treatment of relapsed/refractory multiple myeloma.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Biogen/Eisai's New BAN2401 Study for Alzheimer's Begins
by Zacks Equity Research
A new phase III study has been initiated to evaluate Biogen (BIIB) and Eisai's BAN2401 to treat preclinical Alzheimer's disease.
Biogen Files BLA for Alzheimer's Drug Aducanumab, Stock Up
by Zacks Equity Research
If Biogen's (BIIB) aducanumab is approved by the FDA, it will become the first medicine to be approved to reduce the clinical decline associated with Alzheimer's disease.
Endo (ENDP) Obtains FDA Approval for Cellulite Treatment
by Zacks Equity Research
Endo (ENDP) gains FDA approval for Qwo (collagenase clostridium histolyticum-aaes) for the treatment of cellulite.
Novartis Gets EC Approval for Enerzair Breezhaler for Asthma
by Zacks Equity Research
Novartis (NVS) gets EC approval for Enerzair Breezhaler as a maintenance treatment for asthma.
The Zacks Analyst Blog Highlights: Novartis, Equinix, Newmont, Enterprise Products Partners and Franco-Nevada
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Novartis, Equinix, Newmont, Enterprise Products Partners and Franco-Nevada
Top Analyst Reports for Novartis, Equinix & Newmont
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Novartis (NVS), Equinix (EQIX) and Newmont (NEM).
Amgen Gets Favorable Appeals Court Ruling for Enbrel Patent
by Zacks Equity Research
An appeals court ruled in Amgen's (AMGN) favor in a case challenging the validity of two patents on its top-selling medicine, Enbrel.
Novartis Gets Positive CHMP View for Cosentyx Label Expansion
by Zacks Equity Research
Novartis' (NVS) Cosentyx gets positive CHMP opinion for moderate-to-severe plaque psoriasis in children and adolescents aged 6-18 years.
Bristol Myers & Acceleron Obtain EC Approval for Reblozyl
by Zacks Equity Research
Bristol Myers (BMY) and partner Acceleron win EC approval of Reblozyl (luspatercept) for two indications.
AbbVie's Eye Disorder Candidate Gets Complete Response Letter
by Zacks Equity Research
AbbVie (ABBV) unit Allergan's abicipar pegol demonstrates unfavorable benefit-risk ratio in patients with nAMD, an eye disorder. The FDA issues a complete response letter.
Global Blood to Seek Approval of Oxbryta in Europe for SCD
by Zacks Equity Research
Global Blood (GBT) plans to seek approval for Oxbryta tablets to treat hemolytic anemia in SCD patients aged 12 years and older in Europe.
Novartis Discontinues HCQ Study Due to Enrollment Challenges
by Zacks Equity Research
Novartis (NVS) abandons its HCQ study in COVID-19 patients due to enrollment challenges.
Alpine Skyrockets on License Deal With AbbVie for ALPN-101
by Zacks Equity Research
Alpine (ALPN) signs an agreement with AbbVie granting exclusive worldwide option and license to its pipeline candidate, ALPN-101. The deal significantly boosts Alpine's funds.